Skip to content

Study on the clinical efficacy and mechanism of vascular recanalization therapy combined with nano selenium capsules in patients with acute ischemic stroke

Study on the clinical efficacy and mechanism of vascular recanalization therapy combined with nano selenium capsules in patients with acute ischemic stroke

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113293
Enrollment
Unknown
Registered
2025-11-26
Start date
2023-04-29
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

vascular recanalization therapy combined with oral nano selenium capsules:oral nano selenium capsules
vascular recanalization therapy:none

Sponsors

Zhuhai People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Clinically diagnosed with acute ischemic stroke; 2.Occlusion of large vessels in the anterior or posterior circulation; 3.CT excludes intracranial hemorrhage; 4.NIHSS>=6; 5.Age >= 18 years old; 6.Signed written informed consent;

Exclusion criteria

Exclusion criteria: 1.mRS>2 before stroke; 2.Blood pressure>185/110 mmHg; 3.blood sugar22.2 mmol/L; 4.Cerebral infarction within the previous 6 weeks, with neurological deficits or neuroimaging showing signs of recent infarction; 5.History of major head trauma in the past 3 months; 6.Major surgery or severe trauma within the last 2 weeks; 7.Gastrointestinal or urinary bleeding in the past 3 weeks; 8.previous intracranial hemorrhage; 9.Use of anticoagulants, INR > 1.7 or 48 hours of oral administration of new anticoagulants; 10.Known platelet count<100 x 109/L;

Design outcomes

Primary

MeasureTime frame
mRS Score;

Secondary

MeasureTime frame
NIHSS Score;Changes in the expression levels of oxidative stress markers (ROS, MDA, SOD, 12-HETE) in peripheral blood;Mortality within 45 days;Changes in blood selenium content and expression of related selenoenzymes (GPx1-4, TrxR, SEPP).;

Countries

China

Contacts

Public ContactYu Liu

Zhuhai People's Hospital

liuyuly1982@163.com+86 756 222 2569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026